Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Aclaris Therapeutics: Clinical Trials & FDA Approval Profile

Aclaris Therapeutics (Global / Institutional) sponsors 18 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 1 active protocols (0 recruiting now), 14 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)16.7%
Median Closed Enrollment vs National (145 pts)53 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Aclaris Therapeutics
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)18
Active Pipeline (Recruiting Now)1 (0)
Completed vs Stopped Early14 / 3 (16.7%)
Median Closed Actual Enrollment53 participants
Physical Hospital Site Disclosure31.5% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Explore interactive annual charts and M&A subsidiary rollups in the Aclaris Therapeutics Interactive Dossier, benchmark peers in Immunology, Rheumatology, and Dermatology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI